Predicting Antigen Presentation—What Could We Learn From a Million Peptides?
暂无分享,去创建一个
[1] E. Mardis,et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.
[2] Nicholas A Williamson,et al. Secreted HLA recapitulates the immunopeptidome and allows in-depth coverage of HLA A*02:01 ligands. , 2012, Molecular immunology.
[3] Magdalini Moutaftsi,et al. A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.
[4] H. Rammensee,et al. SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.
[5] Ruedi Aebersold,et al. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. , 2015, Molecular & cellular proteomics : MCP.
[6] Mathieu Courcelles,et al. Comparison of the MHC I Immunopeptidome Repertoire of B‐Cell Lymphoblasts Using Two Isolation Methods , 2018, Proteomics.
[7] J. Greenbaum,et al. Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.
[8] José A. Dianes,et al. 2016 update of the PRIDE database and its related tools , 2015, Nucleic Acids Res..
[9] Andreas Handel,et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells , 2017, Nature.
[10] Markus Müller,et al. Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome , 2018, bioRxiv.
[11] Pingping Guan,et al. EpiJen: a server for multistep T cell epitope prediction , 2006, BMC Bioinformatics.
[12] F. Bootz,et al. The MHC Class II Immunopeptidome of Lymph Nodes in Health and in Chemically Induced Colitis , 2017, The Journal of Immunology.
[13] M. Nielsen,et al. Predicted MHC peptide binding promiscuity explains MHC class I ‘hotspots’ of antigen presentation defined by mass spectrometry eluted ligand data , 2018, Immunology.
[14] Scheherazade Sadegh-Nasseri,et al. MHC Class II Auto-Antigen Presentation is Unconventional , 2015, Front. Immunol..
[15] J. Utikal,et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.
[16] Alex Rubinsteyn,et al. Predicting Peptide-MHC Binding Affinities with Imputed Training Data , 2016, bioRxiv.
[17] John Sidney,et al. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules , 2003, Bioinform..
[18] Wei Jiang,et al. High-throughput engineering and analysis of peptide binding to class II MHC , 2010, Proceedings of the National Academy of Sciences.
[19] Lloyd J. Old,et al. Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.
[20] K. Cibulskis,et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. , 2014, Blood.
[21] Ash A. Alizadeh,et al. Antigen Presentation Profiling Reveals Recognition of Lymphoma Immunoglobulin Neoantigens , 2017, Nature.
[22] H. Rammensee,et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[23] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[24] Bjoern Peters,et al. Deciphering the MHC-associated peptidome: a review of naturally processed ligand data , 2017, Expert review of proteomics.
[25] Clemencia Pinilla,et al. Derivation of an amino acid similarity matrix for peptide:MHC binding and its application as a Bayesian prior , 2009, BMC Bioinformatics.
[26] A. Bentzen,et al. Evolution of MHC-based technologies used for detection of antigen-responsive T cells , 2017, Cancer Immunology, Immunotherapy.
[27] T. Schumacher,et al. Dissection of T-cell antigen specificity in human melanoma. , 2012, Cancer research.
[28] David Gfeller,et al. Current tools for predicting cancer-specific T cell immunity , 2016, Oncoimmunology.
[29] M. Mann,et al. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. , 2015, Gastroenterology.
[30] J. Neefjes,et al. Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.
[31] Y. Welte,et al. High Immunogenicity of the Human Leukocyte Antigen Peptidomes of Melanoma Tumor Cells* , 2012, The Journal of Biological Chemistry.
[32] Timothy E. Elliott,et al. A quantitative assay of peptide‐dependent class I assembly , 1991, European journal of immunology.
[33] Ilan Beer,et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor‐specific antigens , 2002, European journal of immunology.
[34] Morten Nielsen,et al. Improved Prediction of Bovine Leucocyte Antigens (BoLA) Presented Ligands by Use of Mass-Spectrometry-Determined Ligand and in Vitro Binding Data , 2017, Journal of proteome research.
[35] L. Stern,et al. HLA-DM Focuses on Conformational Flexibility Around P1 Pocket to Catalyze Peptide Exchange , 2013, Front. Immunol..
[36] J. Rossjohn,et al. The molecular basis for peptide repertoire selection in the human leukocyte antigen (HLA) C*06:02 molecule , 2017, The Journal of Biological Chemistry.
[37] Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.
[38] T. Schumacher,et al. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification , 2014, Oncoimmunology.
[39] N. Croft,et al. A comprehensive analysis of peptides presented by HLA-A1. , 2015, Tissue antigens.
[40] G. Coukos,et al. The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands , 2018, The Journal of Immunology.
[41] J. Castle,et al. Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.
[42] S. Sadegh-Nasseri,et al. Determinants of immunodominance for CD4 T cells. , 2015, Current opinion in immunology.
[43] M. Nielsen,et al. Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01 , 2017, The Journal of Biological Chemistry.
[44] S. Sadegh-Nasseri. A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells , 2016, F1000Research.
[45] Ton N. Schumacher,et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.
[46] Michael R Stratton,et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.
[47] Morten Nielsen,et al. Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..
[48] J. Sidney,et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.
[49] A. Nesvizhskii. Proteogenomics: concepts, applications and computational strategies , 2014, Nature Methods.
[50] B. Walker,et al. Crystal structure of HLA-B*5801 with a TW10 HIV Gag epitope reveals a novel mode of peptide presentation , 2017, Cellular &Molecular Immunology.
[51] J. Castle,et al. Targeting the tumor mutanome for personalized vaccination therapy , 2012, Oncoimmunology.
[52] R. Henderson,et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.
[53] Hans-Georg Rammensee,et al. Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices , 2017, The Journal of Immunology.
[54] P. Kloetzel,et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding , 2005, Cellular and Molecular Life Sciences CMLS.
[55] M. Ciudad,et al. Composition of the HLA‐DR‐associated human thymus peptidome , 2013, European journal of immunology.
[56] Albert J R Heck,et al. Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD) , 2014, Proceedings of the National Academy of Sciences.
[57] Pingping Guan,et al. MHCPred: a server for quantitative prediction of peptide-MHC binding , 2003, Nucleic Acids Res..
[58] Peter Cresswell,et al. Pathways of antigen processing. , 2013, Annual review of immunology.
[59] L. Jensen,et al. Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.
[60] F. Sinigaglia,et al. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries , 1992, The Journal of experimental medicine.
[61] Z. Szallasi,et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes , 2016, Nature Biotechnology.
[62] K Kumagai,et al. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. , 1987, Journal of immunological methods.
[63] M. Nielsen,et al. NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.
[64] Ilan Beer,et al. Soluble plasma HLA peptidome as a potential source for cancer biomarkers , 2010, Proceedings of the National Academy of Sciences.
[65] J. Gartner,et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.
[66] A. Purcell,et al. Revisiting the Arthritogenic Peptide Theory: Quantitative Not Qualitative Changes in the Peptide Repertoire of HLA–B27 Allotypes , 2015, Arthritis & rheumatology.
[67] P. Kloetzel,et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides , 2016, Science.
[68] Jian Wang,et al. PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity , 2017, GigaScience.
[69] Mark Lindsey,et al. Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501 , 1997, Immunogenetics.
[70] Dongsup Kim,et al. Deep convolutional neural networks for pan-specific peptide-MHC class I binding prediction , 2017, BMC Bioinformatics.
[71] Dario Neri,et al. High‐resolution analysis of the murine MHC class II immunopeptidome , 2016, European journal of immunology.
[72] Dario Neri,et al. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes , 2016, Cancer Immunology, Immunotherapy.
[73] David Gfeller,et al. Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide–HLA Interactions , 2016, The Journal of Immunology.
[74] Hans-Georg Rammensee,et al. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy , 2004, Cancer Immunology, Immunotherapy.
[75] L. Stern,et al. Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization , 2014, Current protocols in immunology.
[76] K. Garcia,et al. The Intergenic Recombinant HLA-B∗46:01 Has a Distinctive Peptidome that Includes KIR2DL3 Ligands , 2017, Cell Reports.
[77] J. Gartner,et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.
[78] O. Lund,et al. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage , 2005, Immunogenetics.
[79] D. Neri,et al. Membranal and Blood‐Soluble HLA Class II Peptidome Analyses Using Data‐Dependent and Independent Acquisition , 2018, Proteomics.
[80] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[81] Yu Shyr,et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.
[82] Clemencia Pinilla,et al. Measurement of MHC/Peptide Interactions by Gel Filtration or Monoclonal Antibody Capture , 2013, Current protocols in immunology.
[83] Morten Nielsen,et al. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions , 2011, Immunogenetics.
[84] Morten Nielsen,et al. Immunological bioinformatics , 2005, Computational molecular biology.
[85] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[86] M. Nielsen,et al. Footprints of antigen processing boost MHC class II natural ligand binding predictions , 2018, bioRxiv.
[87] A. Sewell,et al. Real time detection of peptide–MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability , 2011, Molecular immunology.
[88] T. Schumacher,et al. Generation of peptide–MHC class I complexes through UV-mediated ligand exchange , 2006, Nature Protocols.
[89] Shabaz Mohammed,et al. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity* , 2016, Molecular & Cellular Proteomics.
[90] V. Crotzer,et al. Autophagy and Its Role in MHC-Mediated Antigen Presentation1 , 2009, The Journal of Immunology.
[91] D. Ferrington,et al. Immunoproteasomes: structure, function, and antigen presentation. , 2012, Progress in molecular biology and translational science.
[92] Stefan Tenzer,et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. , 2009, Nature immunology.
[93] A. Prescott,et al. Enhanced Dendritic Cell Antigen Capture via Toll-Like Receptor-Induced Actin Remodeling , 2004, Science.
[94] E. Caron,et al. The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.
[95] Chee Keong Kwoh,et al. PREDTAP: a system for prediction of peptide binding to the human transporter associated with antigen processing , 2006, Immunome research.
[96] Markus Müller,et al. ‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization , 2017, Front. Immunol..
[97] Edward J. Collins,et al. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site , 1994, Nature.
[98] Dario Neri,et al. High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera , 2016, Proteomics.
[99] Gary D Bader,et al. The multiple-specificity landscape of modular peptide recognition domains. , 2011 .
[100] Morten Nielsen,et al. The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding , 2009, Bioinform..
[101] Morten Nielsen,et al. Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity , 2012, European journal of immunology.
[102] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[103] Hidde L. Ploegh,et al. The known unknowns of antigen processing and presentation , 2008, Nature Reviews Immunology.
[104] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[105] Roman A. Zubarev,et al. The SysteMHC Atlas project , 2017, Nucleic Acids Res..
[106] M. Nielsen,et al. Machine learning reveals a non‐canonical mode of peptide binding to MHC class II molecules , 2017, Immunology.
[107] M. Lotze,et al. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[108] David Gfeller,et al. Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity , 2017, bioRxiv.
[109] M. Maeurer,et al. Peptide Microarray-Based Identification of Mycobacterium tuberculosis Epitope Binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401 , 2009, Clinical and Vaccine Immunology.
[110] Anne M Evans,et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy , 2006, Proceedings of the National Academy of Sciences.
[111] Jennifer G. Abelin,et al. Mass Spectrometry Profiling of HLA‐Associated Peptidomes in Mono‐allelic Cells Enables More Accurate Epitope Prediction , 2017, Immunity.
[112] Brian J. Stevenson,et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer , 2018, Nature Communications.
[113] Morten Nielsen,et al. GibbsCluster: unsupervised clustering and alignment of peptide sequences , 2017, Nucleic Acids Res..
[114] Juan Antonio Vizcaíno,et al. Minimal Information About an Immuno‐Peptidomics Experiment (MIAIPE) , 2018, Proteomics.
[115] Sri H. Ramarathinam,et al. A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides. , 2014, Tissue antigens.
[116] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[117] Morten Nielsen,et al. Computational Tools for the Identification and Interpretation of Sequence Motifs in Immunopeptidomes , 2018, Proteomics.
[118] Jamie K Teer,et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens , 2016, Oncotarget.
[119] Deborah Hix,et al. The immune epitope database (IEDB) 3.0 , 2014, Nucleic Acids Res..
[120] T. Elliott,et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. , 1999, Journal of immunology.
[121] F. Glaser,et al. The Peptide Repertoire of HLA‐B27 may include Ligands with Lysine at P2 Anchor Position , 2018, Proteomics.
[122] Sri H. Ramarathinam,et al. Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes , 2009, Proceedings of the National Academy of Sciences.
[123] T. Sicheritz-Pontén,et al. Comparative performance of the BGISEQ-500 vs Illumina HiSeq2500 sequencing platforms for palaeogenomic sequencing , 2017, GigaScience.
[124] Alessandro Sette,et al. Properties of MHC Class I Presented Peptides That Enhance Immunogenicity , 2013, PLoS Comput. Biol..
[125] Bjoern Peters,et al. Insights into HLA-Restricted T Cell Responses in a Novel Mouse Model of Dengue Virus Infection Point toward New Implications for Vaccine Design , 2011, The Journal of Immunology.
[126] L. Stern,et al. Evaluating the Role of HLA-DM in MHC Class II–Peptide Association Reactions , 2015, The Journal of Immunology.
[127] T. Elliott,et al. Assembly of MHC class I molecules analyzed in vitro , 1990, Cell.
[128] N. Wentzensen,et al. A systematic review of humoral immune responses against tumor antigens , 2009, Cancer Immunology, Immunotherapy.
[129] P. Roche,et al. The ins and outs of MHC class II-mediated antigen processing and presentation , 2015, Nature Reviews Immunology.
[130] Purvesh Khatri,et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes , 2017, Cell.
[131] H. Kalbacher,et al. Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming. , 1993, Journal of immunology.
[132] Markus Müller,et al. High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome* , 2017, Molecular & Cellular Proteomics.
[133] Valerio Zolla,et al. The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity* , 2016, The Journal of Biological Chemistry.
[134] Chris Bailey-Kellogg,et al. A high throughput MHC II binding assay for quantitative analysis of peptide epitopes. , 2014, Journal of visualized experiments : JoVE.
[135] Bjoern Peters,et al. HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.
[136] Maria V. Tejada-Simon,et al. Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.
[137] O. Lund,et al. novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .
[138] T. Schumacher,et al. Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 , 2008, Proceedings of the National Academy of Sciences.
[139] David Gfeller,et al. Uncovering new aspects of protein interactions through analysis of specificity landscapes in peptide recognition domains , 2012, FEBS letters.
[140] S. Lemieux,et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames , 2016, Nature Communications.
[141] J. Drijfhout,et al. Naturally Processed Non-canonical HLA-A*02:01 Presented Peptides* , 2014, The Journal of Biological Chemistry.
[142] S. Lemieux,et al. MHC class I-associated peptides derive from selective regions of the human genome. , 2016, The Journal of clinical investigation.
[143] H. Rammensee,et al. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. , 1994, Journal of immunology.
[144] Morten Nielsen,et al. Uncovering the Peptide-Binding Specificities of HLA-C: A General Strategy To Determine the Specificity of Any MHC Class I Molecule , 2014, The Journal of Immunology.
[145] Jimmy Lin,et al. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.
[146] Gary D. Bader,et al. MUSI: an integrated system for identifying multiple specificity from very large peptide or nucleic acid data sets , 2011, Nucleic acids research.
[147] José A. Dianes,et al. 2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..
[148] Xiaohui Xie,et al. HLA class I binding prediction via convolutional neural networks , 2017, bioRxiv.
[149] Eilon Barnea,et al. Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy * , 2016, Molecular & Cellular Proteomics.
[150] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[151] P. Cresswell,et al. Cellular mechanisms governing cross-presentation of exogenous antigens , 2004, Nature Immunology.
[152] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[153] M. Nielsen,et al. NetMHCstab – predicting stability of peptide–MHC‐I complexes; impacts for cytotoxic T lymphocyte epitope discovery , 2014, Immunology.
[154] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[155] Søren Buus,et al. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays , 2009, Immunome research.
[156] Z. Szallasi,et al. An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes , 2017, Front. Immunol..
[157] M. Mann,et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.
[158] K. Rock,et al. Specialized proteasome subunits play an essential role in thymic selection of CD8+ T cells , 2016, Nature Immunology.
[159] Z. Modrušan,et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.
[160] Alexandre M J J Bonvin,et al. Extended O-GlcNAc on HLA Class-I-Bound Peptides. , 2015, Journal of the American Chemical Society.
[161] Morten Nielsen,et al. Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove , 2016, eLife.
[162] M. Nielsen,et al. The Length Distribution of Class I–Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele–Specific Binding Preference , 2016, The Journal of Immunology.
[163] Markus Wulf,et al. Identification of human MHC class I binding peptides using the iTOPIA- epitope discovery system. , 2009, Methods in molecular biology.
[164] F. Chisari,et al. Role of Immunoproteasome Catalytic Subunits in the Immune Response to Hepatitis B Virus , 2006, Journal of Virology.
[165] F. Pazos,et al. A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens* , 2016, Molecular & Cellular Proteomics.
[166] Hans-Georg Rammensee,et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.
[167] Bjoern Peters,et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries , 2008, Immunome research.
[168] Albert J R Heck,et al. Arginine (Di)methylated Human Leukocyte Antigen Class I Peptides Are Favorably Presented by HLA-B*07. , 2017, Journal of proteome research.
[169] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[170] Maxim N. Artyomov,et al. Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.
[171] J. Voorberg,et al. Analysis of the HLA‐DR peptidome from human dendritic cells reveals high affinity repertoires and nonconventional pathways of peptide generation , 2017, Journal of leukocyte biology.
[172] James Robinson,et al. The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..
[173] Ralf Zimmer,et al. Improved Ribo-seq enables identification of cryptic translation events , 2018, Nature Methods.
[174] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[175] Morten Nielsen,et al. Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach , 2013, Bioinform..
[176] K. Rock,et al. The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules. , 2017, Annual review of immunology.
[177] Morten Nielsen,et al. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction , 2009, BMC Bioinformatics.
[178] Rachel Karchin,et al. Prediction of peptide binding to MHC Class I proteins in the age of deep learning , 2017 .
[179] Eilon Barnea,et al. The Peptidome of Behçet's Disease–Associated HLA–B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1 , 2015, Arthritis & rheumatology.
[180] Sébastien Lemieux,et al. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation , 2011, Molecular systems biology.
[181] N. Hacohen,et al. HLA-Binding Properties of Tumor Neoepitopes in Humans , 2014, Cancer Immunology Research.
[182] Morten Nielsen,et al. Pan-Specific Prediction of Peptide–MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity , 2016, The Journal of Immunology.
[183] D. Egan,et al. High-throughput T-cell epitope discovery through MHC peptide exchange. , 2009, Methods in molecular biology.
[184] Søren Buus,et al. Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. , 2011, Journal of immunological methods.
[185] S. Henikoff,et al. Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[186] G. Coukos,et al. The C-terminal extension landscape of naturally presented HLA-I ligands , 2017, Proceedings of the National Academy of Sciences.
[187] Sri H. Ramarathinam,et al. MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape , 2017, Nature Structural &Molecular Biology.